Core Viewpoint - Supernus Pharmaceuticals, Inc. is set to announce its fourth quarter and full year 2025 financial and business results on February 24, 2026, after market close [1] Group 1: Financial Results Announcement - The financial results will be presented by Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, during a conference call scheduled for February 24, 2026, at 4:30 p.m. ET [2] - A live webcast of the conference call will be available on the Company's Investor Relations website [2] - Participants can pre-register for the call and will receive a personalized conference code for access [3] Group 2: Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases [4] - The Company has a diverse neuroscience portfolio that includes approved treatments for various conditions such as ADHD, Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [5]

Core Insights - Supernus Pharmaceuticals, Inc. is set to present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025, at 3:20 p.m. ET, with Jack A. Khattar, the President and CEO, leading the presentation [1] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [3] - The company has a diverse neuroscience portfolio that includes approved treatments for various conditions such as ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] Conference Details - Investors interested in meeting with company management during the conference can contact the Bank of America conference coordinator [2] - A live audio webcast of the presentation will be available, and an archived replay will be accessible for 60 days following the conference on the company's website [2]

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1][2] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [3][4] - The company's diverse neuroscience portfolio includes approved treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4]

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the 2025 Jefferies Global Healthcare Conference in London on November 17, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1] - The company focuses on developing and commercializing products for central nervous system (CNS) diseases [3][4] Company Overview - Supernus Pharmaceuticals specializes in treatments for various CNS disorders, including ADHD, Parkinson's disease-related dyskinesia, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] - The company is also developing a range of novel product candidates targeting CNS disorders [4] Investor Relations - Investors interested in meeting with company management during the conference can contact the Jefferies conference coordinator [2] - A live audio webcast of the presentation will be available, with an archived replay accessible for 60 days post-conference [2]

Core Insights - Supernus Pharmaceuticals, Inc. is participating in multiple investor conferences in September 2025, showcasing its focus on central nervous system (CNS) diseases [1][2][3] Conference Details - The company will present at the Cantor Global Healthcare Conference on September 3, 2025, at 8:00 a.m. ET in New York [1] - The Wells Fargo Healthcare Conference is scheduled for September 4, 2025, at 8:45 a.m. ET in Everett, MA [2] - The TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit will take place virtually on September 18, 2025, at 10:40 a.m. ET [3] Webcast Information - A live audio webcast of the presentations will be available on the Supernus Pharmaceuticals website, with archived replays accessible for 60 days post-conference [4] Company Overview - Supernus Pharmaceuticals specializes in developing and commercializing products for CNS diseases, with a diverse portfolio that includes treatments for ADHD, Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [5][6]

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the 2025 Jefferies Global Healthcare Conference on June 4, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1] - The company focuses on developing and commercializing products for central nervous system (CNS) diseases [3][4] Company Overview - Supernus Pharmaceuticals specializes in treatments for CNS diseases, including ADHD, dyskinesia in Parkinson's disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] - The company is also developing new potential treatments for epilepsy, depression, and other CNS disorders [4] Conference Details - Investors can arrange meetings with company management during the conference by contacting the Jefferies conference coordinator [2] - A live audio webcast of the presentation will be available, with an archived replay accessible for 60 days post-conference [2]